Skip to main content
. 2019 Mar 29;11(4):307. doi: 10.3390/v11040307

Figure 5.

Figure 5

Effect of PPP1CB phosphatase activity on CSFV replication. SK6 cells were pretreated with no drug, PPP1CB phosphatase inhibitor Okadaic Acid (OA), phosphatase activator Ceramide (C6) or no treatment (NT) followed by infection with CSFV (MOI:1) or mock for 2 h. Time points were collected 0 and 24 h post infection (hpi). (A) Viral yields from CSFV infection in SK6 cells treated as indicated. Titers were determined in SK6 cells and expressed as the log 10 TCID 50 /mL, +/−standard error from triplicate samples (OA: Okadaic Acid, C6: Ceramide) ** p Value: <0.01). (B) Whole-cell lysates were collected 24 hpi. Immunoblotting with an E2-specific antibody (band is 55 kDa as expected) showed a decrease in E2 protein concentration with C6 treatment compared to OA and NT (lane 6 vs. 4 and 5). An α-Tubulin-specific antibody was used as a loading control (band is at 50 kDa as expected).